natgillin/translations-raw huggingface dataset:
Zinacef is an antibiotic used to treat certain bacterial infections, including pneumonia (infection of the lungs), urinary tract infections (infections of the structures that carry urine), soft-tissue infections (infections of tissues just below the skin), infections within the abdomen, as well as to prevent infections during surgery. 
Zdravilo Zinacef je antibiotik, ki se uporablja za zdravljenje določenih bakterijskih okužb, vključno s pljučnico (okužba pljuč), okužbami sečil (okužbe struktur, ki proizvajajo in odvajajo urin), okužbami mehkih tkiv (okužbe podkožnih tkiv) in okužbami v trebušni votlini, ter za preprečevanje okužb med kirurškimi posegi.
The CHMP also decided that Zinacef should no longer be used in sequential therapy (when switching patients from an injectable to an oral treatment) due to a significant reduction in exposure to the active substance when switching to the oral formulation. 
CHMP je odločil tudi, da se zdravilo Zinacef ne sme več uporabljati pri sekvenčnem zdravljenju (pri prehodu bolnikov z injekcij na peroralno zdravljenje) zaradi znatnega zmanjšanja izpostavljenosti zdravilni učinkovini pri prehodu na peroralno farmacevtsko obliko.
• Acute exacerbations (flares-up) of chronic bronchitis. 
• akutnih poslabšanj (izbruhov) kroničnega bronhitisa;
The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU. 
CHMP je ob upoštevanju predloženih podatkov in znanstvenih razprav v okviru Odbora menil, da je treba povzetke glavnih značilnosti zdravila, označevanje in navodila za uporabo uskladiti po vsej EU.
The active substance, cefuroxime sodium, belongs to the group ‘cephalosporins'. 
Zdravilna učinkovina, natrijev cefuroksimat, spada v skupino „cefalosporinov“.
• Soft-tissue infections: cellulitis, erysipelas and wound infections. 
• okužb mehkega tkiva: celulitisa, erizipela in okužb ran;
cardiovascular, and gynaecological surgery (including caesarean section). 
kardiovaskularnih in ginekoloških kirurških posegih (vključno s carskim rezom).
• Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, 
• za preprečevanje okužb pri gastrointestinalnih (vključno z ezofagealnimi), ortopedskih,
On 20 April 2010, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Zinacef in the EU. 
Da bi Evropska komisija uskladila dovoljenja za promet z zdravilom Zinacef v EU, je 20. aprila 2010 zadevo napotila na CHMP.
• Complicated urinary tract infections, including pyelonephritis (kidney infection). 
• zapletenih okužb sečil, vključno s pielonefritisom (okužbo ledvic);
• Intra-abdominal infections. 
• okužb v trebušni votlini;
Zinacef was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh). 
Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Zinacef potrebna uskladitev.
ATCvet code: QI06AA01. 
Oznaka ATC vet: QI06AA01.
PP MANUFACTURING CORPORATION 175 crossing Boulevard, Suite 200, Framingham, Massachusetts 01702, USA 
PP MANUFACTURING CORPORATION 175 Crossing Boulevard, Suite 200, Framingham, Massachusetts 01702, ZDA
A moderate and transient local reaction (<2 cm) is commonly observed after the first injection. 
Zmerna in prehodna lokalna reakcija (<2 cm) je pogosto opažena po prvem cepljenju.
Maternally derived antibodies can negatively influence the immune response to vaccination. 
Maternalna protitelesa lahko negativno vplivajo na imunski odziv na cepivo.
Date of first authorisation: 17/06/2009. 
Datum pridobitve dovoljenja za promet: 17/06/2009 Datum zadnjega podaljšanja : 12/06/2014
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. 
Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini razen z zdraviloma omenjenima zgoraj.
Pharmacotherapeutic group: immunologicals for Felidae, inactivated viral vaccines for cats. 
Farmakoterapevtska skupina: imunološka sredstva za felidae, inaktivirana virusna cepiva za mačke.
In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age. 
V primerih, kjer lahko pričakujemo maternalna protitelesa, je morebiti potrebno še tretje injiciranje v starosti 15
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (http://www.ema.europa.eu/).
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. 
Zdravila ne smete uporabljajati po datumu izteka roka uporabnosti, navedenega na nalepki po EXP.
3% aluminium hydroxide gel expressed as mg Al3+ 
3 % gel aluminijevega hidroksida, izražen kot mg Al3+
Special warnings for each target species: Vaccinate healthy animals only. 
Posebni previdnostni ukrep za vse ciljne vrste: Cepite samo zdrave živali.
Overdose (symptoms, emergency procedures, antidotes): 
Preveliko odmerjanje (simptomi , nujni ukrepi, protistrupi ):
Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease. 
Aktivna imunizacija mačk, starih osem tednov in več, proti mačji levkemiji za preprečevanje trajne viremije in kliničnih znakov povezane bolezni.
Opalescent liquid. 
Opalescentna tekočina.
Special precautions for use in animals: 
Posebni previdnosti ukrepi za uporabo pri živalih:
Plastic or cardboard box of 10 vials. 
Plastična ali kartonska škatla z 10 vialami.
LEUCOGEN suspension for injection for cats 
LEUCOGEN suspenzija za injiciranje za mačke
Plastic or cardboard box of 50 vials. 
Plastična ali kartonska škatla s 50 vialami.
The transient signs following vaccination such as hyperthermia (lasting 1 to 4 days), apathy and digestive disturbances may also be commonly observed. 
Prehodni znaki po cepljenju, kot je hipertermija (ki traja 1 do 4 dni), apatija in motnje prebave so prav tako pogosto opaženi.
Protection against persistent viraemia is observed in 73% of cats 3 weeks after their first vaccine injection. 
Za komponento levkemije se je zaščita pred trajno viremijo pojavila pri 73 odstotkih mačk tri tedne po prejemu prve injekcije cepiva.
Read the package leaflet before use Subcutaneous use 
Pred uporabo preberite navodilo Subkutana uporaba
Shake the vial gently before use. 
Pred uporabo vialo rahlo pretresite.
No adverse reactions were observed after an overdose administration of the veterinary medicinal product other than those mentioned in section 6, except local reactions that can last longer (from 5 to 6 weeks at the most). 
Po dajanju prevelikega odmerka zdravila za uporabo v veterinarski medicini ni bilo opaziti neželenih učinkov, razen tistih, ki so omenjeni v poglavju 6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
Sodium chloride Disodium phosphate anhydrous Potassium dihydrogen phosphate Aluminium hydroxide gel Quillaja saponaria Water for injections 
Natrijev klorid natrijev hidrogenfosfat, brezvodni Kalijev dihidrogenfosfat Aluminijev hidroksid (gel) Quillaja saponaria Voda za injekcije
Do not mix with any other veterinary medicinal product except FELIGEN RCP or FELIGEN CRP. 
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini razen s FELIGEN RCP ali FELIGEN CRP.
A decision to use this vaccine before or after another veterinary medicinal product therefore needs to be made on a case by case basis. 
Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera do primera.
No adverse reactions were observed after an overdose administration (2 doses) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most). 
Po dajanju prevelikega odmerka (2 odmerkov) zdravila za uporabo v veterinarski medicini ni bilo opažena neželenih učinkov, razen tistih, ki so omenjeni v poglavju 4.6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
Type I glass vials containing one dose (1 ml) of the vaccine closed with a 13 mm-diameter butyl elastomer stopper and aluminium capsule. 
Steklena viala tipa I, ki vsebuje en odmerek (1ml) cepiva, zaprta z zamaškom iz butil elastomera, premera 13 mm in z aluminijasto kapsulo.
Vaccine against feline leukaemia. 
Cepivo proti mačji levkemiji.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with FELIGEN CRP and FELIGEN RCP. 
Na voljo so podatki o varnosti in učinkovitosti, ki dokazujejo, da se to cepivo lahko zmeša in daje s FELIGEN CRP in FELIGEN RCP.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Box of 10 or 50 vials 
PODATKI NA ZUNANJI OVOJNINI Škatla z 10 ali 50 vialami
Per dose of 1 ml: 
Vsak odmerek po 1 ml vsebuje:
The onset of immunity has been demonstrated from 3 weeks after the primary vaccination. 
Začetek imunosti je dokazan od 3-eh tednov po prvem cepljenju.
After the primary vaccination course, the duration of immunity lasts for one year. 
Po prvem krogu cepljenja je trajanje imunosti eno leto.
Shelf life after first opening the immediate packaging: use immediately. 
Rok uporabnosti po prvem odprtju stične ovojnine: porabite takoj
De-worming at least 10 days prior to vaccination is recommended. 
Priporočljivo je mačke razglistiti vsaj 10 dni pred cepljenjem.
Special precautions for use in animals De-worming at least 10 days prior to vaccination is recommended. 
Priporočljivo je razglistiti mačke vsaj 10 dni pred cepljenjem.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with FELIGEN CRP or FELIGEN RCP. 
Razpoložljivi podatki o varnosti in učinkovitosti so pokazali, da se to cepivo lahko zmeša in daje z zdravilom FELIGEN CRP ali FELIGEN RCP.
Administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination. 
Odmerek (1ml) zdravila za uporabo v veterinarski medicini dajte subkutano po naslednjem programu cepljenja.
Shake the vial gently and administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination. 
Vialo rahlo pretresite in subkutano dajte odmerek zdravila za uporabo v veterinarski medicini po naslednjem programu cepljenja.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years. 
Po prvem poživilnem cepljenju leto dni po prvem krogu cepljenja, se lahko izvaja nadaljnja cepljenja v intervalih po tri leta.
Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated. 
Po prvem poživilnem cepljenju leto dni po prvem krogu cepljenja je dokazano trajanje imunosti 3 leta.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
Primary vaccination: - first injection in kittens from eight weeks of age - second injection 3 or 4 weeks later. 
- drugo injiciranje 3 ali 4 tedne kasneje.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 
PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA,
Minimum quantity of purified p45 FeLV-envelope antigen: 102 µg 
Učinkovina: Minimalna količina prečiščenega antigena ovojnice p 45FeLV: 102 µg.
Minimum quantity of purified p45 FeLV-envelope antigen 102 µg 
Učinkovina: Minimalna količina prečiščenega antigena ovojnice p 45 FeLV 102 µg
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
Marketing authorisation holder and manufacturer responsible for the batch release VIRBAC 
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za sproščanje serij VIRBAC
EXP {month/year} Once broached use immediately. 
Načeto zdravilo uporabite takoj.
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi za uporabo pri živalih
This overview was last updated in 11-2018. 
Povzetek je bil nazadnje posodobljen 11-2018.
It should be used in combination with safer sex practices, such as use of condoms. 
Uporabljati bi se moral v kombinaciji z varnejšimi spolnimi praksami, na primer uporabo kondomov.
In addition, it may be used in adolescents with HIV who are resistant to first-line treatments or who cannot take them because of side effects. 
Poleg tega se lahko uporablja tudi pri mladostnikih, ki so okuženi z virusom HIV in so odporni proti zdravilom prve izbire ali teh zaradi neželenih učinkov ne morejo jemati.
Emtricitabine/Tenofovir disoproxil Krka received a marketing authorisation valid throughout the EU on 9 December 2016. 
Za zdravilo Emtricitabin/dizoproksiltenofovirat Krka je bilo 9. decembra 2016 izdano dovoljenje za promet, veljavno po vsej EU.
Further information on Emtricitabine/Tenofovir disoproxil Krka can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/EmtricitabineTenofovir-disoproxil-Krka. 
Nadaljnje informacije o zdravilu Emtricitabin/dizoproksiltenofovirat Krka so na voljo na spletni strani agencije: www.ema.europa.eu/medicines/human/EPAR/EmtricitabineTenofovir-disoproxil-Krka.
This means that it contains the same active substances and works in the same way as a ‘reference medicine' already authorised in the EU called Truvada. 
To pomeni, da vsebuje enaki zdravilni učinkovini in ima enak način delovanja kot referenčno zdravilo Truvada, ki je že odobreno v EU.
If patients need to stop taking emtricitabine or tenofovir, or need to take different doses, they will need to take medicines containing emtricitabine or tenofovir disoproxil separately. 
Če bi morali bolniki prekiniti jemanje emtricitabina ali tenofovirja oziroma bi bilo treba njune odmerke spremeniti, bodo morali jemati zdravila, ki ločeno vsebujejo emtricitabin ali dizoproksiltenofovirat.
Studies on the benefits and risks of the active substances in the authorised uses have already been carried out with the reference medicine, Truvada, and do not need to be repeated for Emtricitabine/Tenofovir disoproxil Krka. 
Študije o koristih in tveganjih zdravilnih učinkovin pri dovoljenih uporabah so že bile izvedene z referenčnim zdravilom Truvada, zato jih ni treba ponoviti za zdravilo Emtricitabin/dizoproksiltenofovirat Krka.
The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Krka has been shown to have comparable quality and to be bioequivalent to Truvada. 
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Emtricitabin/dizoproksiltenofovirat Krka primerljivo raven kakovosti kot referenčno zdravilo Truvada ter da mu je biološko enakovredno.
Healthcare professionals will also receive a brochure and reminder card to hand out to individuals receiving the medicine for preexposure prophylaxis. 
Zdravstveni delavci bodo prav tako prejeli brošuro in opozorilno kartico za posameznike, ki jemljejo zdravilo za predekspozicijsko profilakso.
Because Emtricitabine/Tenofovir disoproxil Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Emtricitabin/dizoproksiltenofovirat Krka generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Side effects reported with Emtricitabine/Tenofovir disoproxil Krka are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Emtricitabin/dizoproksiltenofovirat Krka, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
An overview of Emtricitabine/Tenofovir disoproxil Krka and why it is authorised in the EU 
Pregled zdravila Emtricitabin/dizoproksiltenofovirat Krka in zakaj je odobreno v EU
Emtricitabine/Tenofovir disoproxil Krka is available as tablets (200 mg emtricitabine and 245 mg tenofovir disoproxil). 
Zdravilo Emtricitabin/dizoproksiltenofovirat Krka je na voljo v obliki tablet (200 mg emtricitabina in 245 mg dizoproksiltenofovirata).
For the treatment of HIV-1 infection, Emtricitabine/Tenofovir disoproxil Krka, taken in combination with at least one other antiviral medicine, reduces the amount of HIV in the blood and keeps it at a low level. 
Pri zdravljenju okužbe z virusom HIV-1 zdravilo Emtricitabin/dizoproksiltenofovirat Krka v kombinaciji z vsaj enim protivirusnim zdravilom zniža količino virusa HIV v krvi in jo zadržuje na nizki ravni.
What measures are being taken to ensure the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Emtricitabin/dizoproksiltenofovirat Krka?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emtricitabine/Tenofovir disoproxil Krka have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Emtricitabin/dizoproksiltenofovirat Krka upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Emtricitabine/Tenofovir disoproxil Krka is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). 
Emtricitabin/dizoproksiltenofovirat Krka je zdravilo proti virusu HIV, ki se uporablja v kombinaciji z vsaj enim drugim zdravilom te vrste za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
For more information about using Emtricitabine/Tenofovir disoproxil Krka, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Emtricitabin/dizoproksiltenofovirat Krka glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
As for all medicines, data on the use of Emtricitabine/Tenofovir disoproxil Krka are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Emtricitabin/dizoproksiltenofovirat Krka stalno spremljajo.
Emtricitabine/Tenofovir disoproxil Krka is also used to help prevent sexually transmitted HIV-1 infection in adults and adolescents who are at high risk of being infected (pre-exposure prophylaxis or PrEP). 
Zdravilo Emtricitabin/dizoproksiltenofovirat Krka se uporablja tudi kot pomoč za preprečevanje spolno prenosljive okužbe z virusom HIV-1 pri odraslih in mladostnikih, pri katerih je tveganje za okužbo veliko (predekspozicijska profilaksa oziroma PrEP).
As for every medicine, the company provided studies on the quality of Emtricitabine/Tenofovir disoproxil Krka. 
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Emtricitabin/dizoproksiltenofovirat Krka.
Other information about Emtricitabine/Tenofovir disoproxil Krka 
Druge informacije o zdravilu Emtricitabin/dizoproksiltenofovirat Krka
Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected. 
Emtricitabin in tenofovir podobno zavirata dejavnost reverzne transkriptaze, tj. encima, ki ga tvori virus HIV in ki mu omogoča, da se lahko razmnožuje v celicah, ki jih je virus okužil.
What are the benefits and risks of Emtricitabine/Tenofovir disoproxil Krka? 
Kakšne so koristi in tveganja, povezani z zdravilom Emtricitabin/dizoproksiltenofovirat Krka?
The company that markets Emtricitabine/Tenofovir disoproxil Krka will provide an information pack to doctors which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Krka on kidney function, and information about use for pre-exposure prophylaxis. 
Družba, ki trži zdravilo Emtricitabin/dizoproksiltenofovirat Krka, bo pripravila informacijsko gradivo za zdravnike, ki bo obsegalo opis možnih škodljivih učinkov zdravila za delovanje ledvic pri jemanju tega zdravila in informacije o njegovi uporabi za predekspozijsko profilakso.
Emtricitabine/Tenofovir disoproxil Krka can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection. 
Predpisovanje in izdaja zdravila Emtricitabin/dizoproksiltenofovirat Krka je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Emtricitabine/Tenofovir disoproxil Krka (emtricitabine / tenofovir disoproxil) 
Emtricitabin/dizoproksiltenofovirat Krka (emtricitabin/dizoproksiltenofovirat)
Emtricitabine/Tenofovir disoproxil Krka does not cure HIV infection or AIDS, but it holds off the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo ne zdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Emtricitabine/Tenofovir disoproxil Krka contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir. 
Zdravilo Emtricitabin/dizoproksiltenofovirat Krka vsebuje dve zdravilni učinkovini: emtricitabin, ki je nukleozidni zaviralec reverzne transkriptaze, in dizoproksiltenofovirat, ki je „predzdravilo“ tenofovirja.
What is Emtricitabine/Tenofovir disoproxil Krka and what is it used for? 
Kaj je zdravilo Emtricitabin/dizoproksiltenofovirat Krka in za kaj se uporablja?
Therefore, the Agency's view was that, as for Truvada, the benefit of Emtricitabine/Tenofovir disoproxil Krka outweighs the identified risk and it can be authorised for use in the EU. 
Zato je menila, da koristi zdravila Emtricitabin/dizoproksiltenofovirat Krka, enako kot pri zdravilu Truvada, odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
Why is Emtricitabine/Tenofovir disoproxil Krka authorised in the EU? 
Zakaj je bilo zdravilo Pemetreksed Krka odobreno v EU?
For pre-exposure prophylaxis of HIV-1 infection, it is expected that Emtricitabine/Tenofovir disoproxil Krka in the blood will stop the virus from multiplying and spreading from the site of infection in case the individual is exposed to the virus. 
Pričakuje se, da zdravilo Emtricitabin/dizoproksiltenofovirat Krka v krvi za predekspozicijsko profilakso pred okužbo z virusom HIV-1 v primeru izpostavljenosti posameznika virusu prepreči razmnoževanje in širjenje virusa z mesta okužbe.
Emtricitabine/Tenofovir disoproxil Krka contains two active substances, emtricitabine and tenofovir disoproxil. 
Zdravilo Emtricitabin/dizoproksiltenofovirat Krka vsebuje dve zdravilni učinkovini, emtricitabin in dizoproksiltenofovirat.
How is Emtricitabine/Tenofovir disoproxil Krka used? 
Kako se zdravilo Emtricitabin/dizoproksiltenofovirat Krka uporablja?
How has Emtricitabine/Tenofovir disoproxil Krka been studied? 
Kako je bilo zdravilo Emtricitabin/dizoproksiltenofovirat Krka raziskano?